Replies to post #212755 on Biotech Values

[DewDiligence]

Correction—FDA advisory panel rejects JNJ’s sirukumab:

http://www.prnewswire.com/news-releases/fda-advisory-committee-does-not-recommend-approval-of-sirukumab-for-the-treatment-of-moderately-to-severely-active-rheumatoid-arthritis-300498749.html

A previous post incorrectly said the panel had voted for approval.